Longboard Pharmaceuticals Inc
Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel and transformative medicines for neurological diseases. The company develops bexicaserin (LP352), which has completed Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies. It also develops LP659, an S1P receptor modulator for the… Read more
Longboard Pharmaceuticals Inc (LBPH) - Total Assets
Latest total assets as of September 2024: $297.00 Million USD
Based on the latest financial reports, Longboard Pharmaceuticals Inc (LBPH) holds total assets worth $297.00 Million USD as of September 2024.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Longboard Pharmaceuticals Inc - Total Assets Trend (2020–2023)
This chart illustrates how Longboard Pharmaceuticals Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Longboard Pharmaceuticals Inc - Asset Composition Analysis
Current Asset Composition (December 2023)
Longboard Pharmaceuticals Inc's total assets of $297.00 Million consist of 99.1% current assets and 0.9% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 28.3% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2020–2023)
This chart illustrates how Longboard Pharmaceuticals Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Longboard Pharmaceuticals Inc's current assets represent 99.1% of total assets in 2023, an increase from 98.4% in 2020.
- Cash Position: Cash and equivalents constituted 28.3% of total assets in 2023, down from 98.4% in 2020.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2020.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Longboard Pharmaceuticals Inc Competitors by Total Assets
Key competitors of Longboard Pharmaceuticals Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Longboard Pharmaceuticals Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Longboard Pharmaceuticals Inc generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Longboard Pharmaceuticals Inc is currently not profitable relative to its asset base.
Longboard Pharmaceuticals Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 15.97 | 8.69 | 17.66 |
| Quick Ratio | 15.97 | 8.69 | 17.66 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $274.68 Million | $ 51.61 Million | $ 52.23 Million |
Longboard Pharmaceuticals Inc - Advanced Valuation Insights
This section examines the relationship between Longboard Pharmaceuticals Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 8.51 |
| Latest Market Cap to Assets Ratio | 29.54 |
| Asset Growth Rate (YoY) | -28.2% |
| Total Assets | $50.70 Million |
| Market Capitalization | $1.50 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Longboard Pharmaceuticals Inc's assets at a significant premium ( 29.54x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Longboard Pharmaceuticals Inc's assets decreased by 28.2% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Longboard Pharmaceuticals Inc (2020–2023)
The table below shows the annual total assets of Longboard Pharmaceuticals Inc from 2020 to 2023.
| Year | Total Assets | Change |
|---|---|---|
| 2023-12-31 | $50.70 Million | -28.21% |
| 2022-12-31 | $70.62 Million | -35.19% |
| 2021-12-31 | $108.95 Million | +93.73% |
| 2020-12-31 | $56.24 Million | -- |